var data={"title":"Ixabepilone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ixabepilone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/336410?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ixabepilone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ixabepilone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708959\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone in combination with capecitabine is contraindicated in patients with AST or ALT greater than 2.5 times the upper limit of normal (ULN) or bilirubin greater than 1 times ULN due to an increased risk of toxicity and neutropenia-related death.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376467\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ixempra Kit</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376473\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antimicrotubular;</li>\n      <li>\n        Antineoplastic Agent, Epothilone B Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376533\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b>  Premedicate with an H<sub>1</sub>-antagonist (eg, oral diphenhydramine 50 mg) and H<sub>2</sub>-antagonist (eg, oral ranitidine 150 to 300 mg) ~1 hour prior to infusion. Patients with a history of hypersensitivity should also be premedicated with corticosteroids (dexamethasone 20 mg orally 1 hour before or IV 30 minutes before infusion). For dose calculation, body surface area (BSA) is capped at a maximum of 2.2 m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Breast cancer (metastatic or locally advanced):</b> IV: 40 mg/m<sup>2</sup>/dose over 3 hours every 3 weeks (maximum dose: 88 mg) either as monotherapy or in combination with capecitabine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosage adjustment with concomitant strong CYP3A4 inhibitors/inducers:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>CYP3A4 inhibitors:</i> Avoid concomitant administration with strong CYP3A4 inhibitors (eg, itraconazole, ketoconazole, voriconazole, clarithromycin, telithromycin, nefazodone, atazanavir, delavirdine, indinavir, nelfinavir, ritonavir, saquinavir); if concomitant administration with a strong CYP3A4 inhibitor cannot be avoided, consider a dose reduction to 20 mg/m<sup>2</sup>. When a strong CYP3A4 inhibitor is discontinued, allow ~1 week to elapse prior to adjusting ixabepilone dose upward to the indicated dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>CYP3A4 inducers:</i> Avoid concomitant administration with strong CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, phenobarbital); if concomitant administration with a strong CYP3A4 inducer cannot be avoided and after maintenance on the strong CYP3A4 inducer is established, consider adjusting the ixabepilone dose gradually up to 60 mg/m<sup>2</sup> (as a 4-hour infusion), with careful monitoring. If the strong CYP3A4 enzyme inducer is discontinued, reduce ixabepilone dose to the dose used prior to initiation of the CYP3A4 inducer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376528\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376529\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling, however, renal excretion is minimal. Pharmacokinetics (monotherapy) are not affected in patients with mild-to-moderate renal insufficiency (CrCl &gt;30 mL/minute); monotherapy has not been studied in patients with serum creatinine &gt;1.5 times ULN. Combination therapy with capecitabine has not been studied in patients with CrCl &lt;50 mL/minute.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376530\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ixabepilone monotherapy (initial cycle; adjust doses for subsequent cycles based on toxicity):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST and ALT &le;2.5 times ULN and bilirubin &le;1 times ULN: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST and ALT &gt;2.5  to &le;10 times ULN and bilirubin &gt;1 to &le;1.5 times ULN: Reduce dose to 32 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST and ALT &le;10 times ULN and bilirubin &gt;1.5 to &le;3 times ULN: Reduce dose to 20 to 30 mg/m<sup>2</sup> (initiate treatment at 20 mg/m<sup>2</sup>, may escalate up to a maximum of 30 mg/m<sup>2</sup> in subsequent cycles if tolerated)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST or ALT &gt;10 times ULN or bilirubin &gt;3 times ULN: Use is not recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Combination therapy of ixabepilone with capecitabine:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST and ALT &le;2.5 times ULN and bilirubin &le;1 times ULN: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AST or ALT &gt;2.5 times ULN or bilirubin &gt;1 times ULN: Use is contraindicated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344419\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:</i> In general, utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based  dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012). <b>Note: </b>According to the manufacturer, patients with a body surface area (BSA) &gt;2.2 m<sup>2</sup> should be dosed based upon a maximum BSA of 2.2 m<sup>2</sup></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376526\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Hematologic:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neutrophils &lt;500/mm<sup>3</sup> for &ge;7 days: Reduce ixabepilone dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neutropenic fever: Reduce ixabepilone dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Platelets &lt;25,000/mm<sup>3</sup> (or &lt;50,000/mm<sup>3</sup> with bleeding): Reduce ixabepilone dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Nonhematologic:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuropathy:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 2 (moderate) for &ge;7 days: Reduce ixabepilone dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 (severe) for &lt;7 days: Reduce ixabepilone dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 (severe or disabling) for &ge;7 days: Discontinue ixabepilone treatment</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 toxicity (severe; other than neuropathy): Reduce ixabepilone dose by 20%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 arthralgia/myalgia or fatigue (transient): Continue ixabepilone at current dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 3 hand-foot syndrome: Continue ixabepilone at current dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Grade 4 toxicity (disabling): Discontinue ixabepilone treatment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Adjust dosage at the start of a cycle are based on toxicities (hematologic and nonhematologic) from the previous cycle; delay new cycles until neutrophils have recovered to &ge;1,500/mm<sup>3</sup>, platelets have recovered to &ge;100,000/mm<sup>3</sup> and nonhematologic toxicities have resolved or improved to at least grade 1. If toxicities persist despite initial dose reduction, reduce dose an additional 20%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Capecitabine dosage adjustments for combination therapy with ixabepilone:</b> Refer to Capecitabine monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376539\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ixempra Kit: 15 mg (1 ea); 45 mg (1 ea) [contains alcohol, usp, cremophor el]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376469\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29038298\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Diluent supplied in Ixempra Kit contains polyoxyethylated castor oil (Cremophor EL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376534\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Infuse over 3 hours. Use non-DEHP administration set (eg, polyethylene); filter with a 0.2 to 1.2 micron inline filter. Administration should be completed within 6 hours of preparation. If the dose is increased (above 40 mg/m<sup>2</sup>) due to concomitant CYP3A4 inducer use, infuse over 4 hours. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132624\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376475\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Breast cancer:</b> Treatment of metastatic or locally-advanced breast cancer resistant to treatment with an anthracycline and a taxane, or if taxane-resistant and further anthracycline therapy is contraindicated (in combination with capecitabine) or as monotherapy in tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Anthracycline resistance is defined as progression during treatment or within 3 months in the metastatic setting (within 6 months in the adjuvant setting). Taxane resistance is defined as progression during treatment within 4 months in the metastatic setting (within 12 months in the adjuvant setting).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376463\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376501\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Percentages reported with monotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral neuropathy (63%; grades 3/4: 14%; grade 3/4 median onset: cycle 4), peripheral sensory neuropathy (62%; grades 3/4: 14%), headache (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (48%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (42%), vomiting (29%), mucositis (&le;29%), stomatitis (&le;29%), diarrhea (22%), anorexia (19%), constipation (16%), abdominal pain (13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Leukopenia (grade 3: 36%; grade 4: 13%), neutropenia (grade 3: 31%; grade 4: 23%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (56%), arthralgia (&le;49%), myalgia (&le;49%), musculoskeletal pain (20%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (9%), chest pain (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral motor neuropathy (10%; grade 3: 1%), pain (8%), dizziness (7%), insomnia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Nail disease (9%), skin rash (9%), palmar-plantar erythrodysesthesia (8%), pruritus (6%), desquamation (2%), hyperpigmentation (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (6%), weight loss (6%), dehydration (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (6%), gastroesophageal reflux (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (grade 3: 6%; grade 4: 2%), febrile neutropenia (3%; grade 3: 3%), thrombocytopenia (grade 3: 5%; grade 4: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Hypersensitivity (5%; grade 3: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Increased lacrimation (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (9%), upper respiratory tract infection (6%), cough (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Mono- and combination therapy: </b> &lt;1%, postmarketing, and/or case reports: Acute hepatic failure, acute pulmonary edema, angina pectoris, atrial flutter, autonomic neuropathy, blood coagulation disorder, cardiomyopathy, cerebral hemorrhage, colitis, delayed gastric emptying, dysphagia, embolism, enterocolitis, erythema multiforme, gastrointestinal hemorrhage, hemorrhage, hypokalemia, hyponatremia, hypotension, hypovolemia, hypovolemic shock, hypoxia, increased gamma-glutamyl transferase, increased serum alkaline phosphatase, increased serum transaminases, interstitial pneumonitis, intestinal obstruction, jaundice, left ventricular dysfunction, metabolic acidosis, myocardial infarction, nephrolithiasis, neutropenic infection, orthostatic hypotension, pneumonia, pneumonitis, radiation recall phenomenon, renal failure, respiratory failure, sepsis, septic shock, supraventricular cardiac arrhythmia, syncope, thrombosis, trismus, urinary tract infection, vasculitis, voice disorder</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376481\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">History of severe (grade 3 or 4) hypersensitivity to polyoxyethylated castor oil (Cremophor EL) or its derivatives; neutrophil count &lt;1,500/mm<sup>3</sup> or platelet count &lt;100,000/mm<sup>3</sup>; combination therapy with ixabepilone and capecitabine in patients with AST or ALT &gt;2.5 times ULN or bilirubin &gt;1 times ULN </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376470\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Dose-dependent myelosuppression, particularly neutropenia, may occur with mono- or combination therapy. Neutropenic fever and infection have been reported with use. The risk for neutropenia is increased with hepatic dysfunction, especially when used in combination with capecitabine. Severe neutropenia and/or thrombocytopenia may require dosage adjustment and/or treatment delay.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cognitive impairment: Due to the ethanol content in the diluent, may cause cognitive impairment; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity: Diluent contains polyoxyethylated castor oil (Cremophor EL), which is associated with hypersensitivity reactions; use is contraindicated in patients with a history of severe hypersensitivity to Cremophor EL or its derivatives. Medications for the treatment of reaction should be available for immediate use; reactions may also be managed by reducing infusion rate. Premedicate with an H<sub>1</sub>- and H<sub>2</sub>-antagonist 1 hour prior to infusion; patients who experience hypersensitivity (eg, bronchospasm, dyspnea, flushing, rash) should also be premedicated with a corticosteroid for all subsequent cycles if treatment is continued. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral neuropathy: Peripheral (sensory and motor) neuropathy occurs commonly; may require dose reductions, treatment delays or discontinuation. Usually occurs during the first 3 cycles. Use with caution in patients with pre-existing neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease. The incidence of MI, ventricular dysfunction and supraventricular arrhythmias is higher when ixabepilone is used in combination with capecitabine (as compared to capecitabine alone). Consider discontinuing ixabepilone in patients who develop cardiac ischemia or impaired cardiac function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution; may have an increased risk for severe peripheral neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: <b>[U.S. Boxed Warning]: Due to increased risk of toxicity and neutropenia-related mortality, combination therapy with capecitabine is contraindicated in patients with AST or ALT &gt;2.5 times ULN or bilirubin &gt;1 times ULN.</b>  Use (as monotherapy) is not recommended if AST or ALT &gt;10 times ULN or bilirubin &gt;3 times ULN; use caution in patients with AST or ALT &gt;5 times ULN; data is limited. In mono- and combination therapy, toxicities and serious adverse reactions are increased with hepatic dysfunction; dosage reductions are necessary.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polyoxyethylated castor oil: Diluent contains polyoxyethylated castor oil (Cremophor EL), which is associated with hypersensitivity reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly; toxicities or serious adverse events with combination therapy may be increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376509\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376508\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8909&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Ixabepilone. Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Ixabepilone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): May decrease the serum concentration of Ixabepilone. Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Ixabepilone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376512\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Grapefruit juice may increase plasma concentrations of ixabepilone. Management: Avoid grapefruit juice.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376476\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376477\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Women of childbearing potential should be advised to use effective contraception during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376480\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ixabepilone is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breast-feeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376524\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid grapefruit juice (may increase plasma concentrations of ixabepilone).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376537\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential; hepatic function (ALT, AST, bilirubin); monitor for hypersensitivity, signs/symptoms of neuropathy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376531\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Epothilone B analog; binds to the beta-tubulin subunit of the microtubule, stabilizing microtubular promoting tubulin polymerization and stabilizing microtubular function, thus arresting the cell cycle (at the G2/M phase) and inducing apoptosis. Activity in taxane-resistant cells has been demonstrated. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376517\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: &gt;1,000 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 67% to 77%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensively hepatic, via CYP3A4; &gt;30 metabolites (inactive) formed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: ~52 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: At the end of infusion (3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (65%; 2% of the total dose as unchanged drug); urine (21%; 6% of the total dose as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324149\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ixempra Kit Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (1): $1,375.58</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">45 mg (1): $4,126.74</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10961931\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ixempra (AR, CH, CL, CO, FR, IL, IN, KR, NZ, SG, TH, TW);</li>\n      <li>Ixemprya (PE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Dendurali N, Low JA, Lee JJ, et al, &ldquo;Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes,&rdquo; <i>J Clin Oncol</i>, 2007, 25(23):3421-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/17606971/pubmed\" target=\"_blank\" id=\"17606971\">17606971</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. <i>J Clin Oncol</i>. 2009;27(19):3104-3108. doi: 10.1200/JCO.2008.20.6995.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/19451430/pubmed\" target=\"_blank\" id=\"19451430\">19451430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ixempra (ixabepilone) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JJ, Low JA, Croarkin E, et al, &ldquo;Changes in Neurologic Function Tests May Predict Neurotoxicity Caused by Ixabepilone,&rdquo; <i>J Clin Oncol</i>, 2006, 24(13):2084-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/16648510/pubmed\" target=\"_blank\" id=\"16648510\">16648510</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Low JA, Wedam SB, Lee JJ, et al, &ldquo;Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2005, 23(12):2726-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/15837987/pubmed\" target=\"_blank\" id=\"15837987\">15837987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mani S, McDid H, Hamilton A, et al, &ldquo;Phase I and Clinical Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B,in Solid Tumors,&rdquo; <i>Clin Cancer Res</i>, 2004, 10(4):1289-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/14977827/pubmed\" target=\"_blank\" id=\"14977827\">14977827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez EA, Lerzo G, Pivot X, et al, &ldquo;Efficacy and Safety of Ixabepilone (BMS-247550), in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane and Capecitabine,&rdquo; <i>J Clin Oncol</i>, 2007, 25(23):3407-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/17606974/pubmed\" target=\"_blank\" id=\"17606974\">17606974</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pivot XB, Li RK, Thomas ES, et al, &ldquo;Activity of Ixabepilone in Oestrogen Receptor-Negative and Oestrogen-Receptor-Progesterone Receptor-Human Epidermal Growth Factor 2-Negative Metastatic Breast Cancer,&rdquo; <i>Eur J Cancer</i>, 2009, 45(17):2940-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/19683429/pubmed\" target=\"_blank\" id=\"19683429\">19683429</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roche H, Yelle L, Cognetti F, et al, &ldquo;Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, as First Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy,&rdquo; <i>J Clin Oncol</i>, 2007, 25(23):3415-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/17606972/pubmed\" target=\"_blank\" id=\"17606972\">17606972</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sparano JA, Vrdoljak E, Rixe O, et al, &ldquo;Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane,&rdquo; <i>J Clin Oncol</i>, 2010, 28(20):3256-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/20530276/pubmed\" target=\"_blank\" id=\"20530276\">20530276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takimoto CH, Liu PY, Lenz H, et al, &ldquo;A Phase I Pharmacokinetic (PK) Study of the Epothilone B Analogue, Ixabepilone (BMS-247550) in Patients (pts) With Advanced Malignancies and Varying Degrees of Hepatic Impairment: A SWOG Early Therapeutics Committee and NCI Organ Dysfunction Working Group Trial,&rdquo; <i>J Clin Oncol</i>, 2006, 24(18S):2004 [abstract 2004 from 2006 ASCO Annual Meeting].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas ES, Gomez HL, Li RK, et al, &ldquo;Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment,&rdquo; <i>J Clin Oncol</i>, 2007, 25(33):5210-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/17968020/pubmed\" target=\"_blank\" id=\"17968020\">17968020</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas E, Tabernero J, Fornier M, et al, &ldquo;Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 2007, 25(23):3399-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ixabepilone-drug-information/abstract-text/17606975/pubmed\" target=\"_blank\" id=\"17606975\">17606975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8909 Version 143.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708959\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F5376467\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F5376473\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F5376533\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F5376528\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F5376529\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5376530\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344419\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F5376526\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F5376539\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F5376469\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F29038298\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F5376534\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132624\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F5376475\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F5376463\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F5376501\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F5376481\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F5376470\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F5376509\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F5376508\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F5376512\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F5376476\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5376477\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F5376480\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F5376524\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5376537\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F5376531\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F5376517\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324149\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F10961931\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8909|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ixabepilone-patient-drug-information\" class=\"drug drug_patient\">Ixabepilone: Patient drug information</a></li></ul></div></div>","javascript":null}